statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

A Closer Look at Vertex Pharmaceuticals's Options Market Dynamics

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the first quarter ended March 31, 2024, and reiterated full year 2024 financial guidance. Vertex...

Vertex Reports First Quarter 2024 Financial Results

Coming up: Federal Reserve officials speak, and Disney, Palantir, and Uber report earnings

 Dania Maxwell / Los Angeles Times via Getty Images

 Key TakeawaysEarnings reports scheduled from...

What To Expect in the Markets This Week

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO (ivacaftor) for the treatment of infants down to 1 month of...

Vertex Announces European Commission Approval for KALYDECO to Treat Infants With Cystic Fibrosis Ages 1 Month and Older

VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE...

VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced important advancements across its suzetrigine pain program, which has the potential to be the first new class of medicine for acute...

Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain

Justin Sullivan / Staff / Getty Images

 Key TakeawaysU.S. equities were mixed at midday Thursday, April 11, 2024 as the latest report on inflation showed wholesale prices rose less than expected...

Top Stock Movers Now: Nike, Constellation Brands, Fastenal, and More

News of the day for April 11, 2024

 Michael M. Santiago / Getty Images

U.S. stock futures are edging lower in premarket trading after tumbling Wednesday on the back of a hotter-than-forecast...

5 Things to Know Before the Stock Market Opens

Deal Values Each Alpine Share at a 38% Premium to Wednesday's Closing Price

 Source: TradingView.com

 Key TakeawaysVertex shares slipped in extended trading Wednesday after the company...

Vertex Stock in Focus After Deal to Buy Alpine Immune For $4.9B Key Level to Watch

Biotech company Vertex Pharmaceuticals said it is acquiring Alpine Immune Sciences in a cash deal valued at $4.9 billion, the company said in a statement on Wednesday. Read more...

Biotech giant Vertex bought Alpine in a cash deal of $4.9 billion

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Watchers	11,158
52-Wk Low	$320.01
52-Wk High	$448.40

Volume	1.06M
52-Wk High	$448.40
52-Wk Low	$320.01

VRTX Vertex Pharmaceuticals, Inc.

About

Feed

News

Sentiment

Earnings

Fundamentals